罗沙司他治疗未接受透析的肾病患者贫血
该3期双盲随机对照试验在中国29个中心纳入154例未接受透析的慢性肾病贫血患者(基线血红蛋白7.0–10.0 g/dl),按2:1随机接受罗沙司他或安慰剂每周三次口服8周,随后18周开放标签期所有患者均接受罗沙司他。主要终点为第7–9周平均血红蛋白较基线变化,罗沙司他组升高1.9±1.2 g/dl,安慰剂组降低0.4±0.8 g/dl(P<0.001)。罗沙司他组铁调素和总胆固醇降幅更大,但高钾血症和代谢性酸中毒更常见。开放标签期疗效维持。
要点
- 未透析慢性肾病患者罗沙司他每周三次口服8周,血红蛋白较基线平均升高1.9±1.2 g/dl,安慰剂组降低0.4±0.8 g/dl(P<0.001)。
- 罗沙司他组铁调素较基线降低56.14±63.40 ng/ml,安慰剂组降低15.10±48.06 ng/ml。
- 罗沙司他组总胆固醇较基线降低40.6 mg/dl,安慰剂组降低7.7 mg/dl。
- 罗沙司他组高钾血症和代谢性酸中毒发生频率高于安慰剂组。
- 18周开放标签期罗沙司他纠正和维持血红蛋白的疗效持续。
适用人群与场景
- 中国未接受透析的慢性肾病患者,基线血红蛋白7.0至10.0 g/dl。
处置流程与药物剂量
- 罗沙司他口服每周三次,疗程8周(随机双盲期);随后18周开放标签期所有患者均接受罗沙司他,期间不给予肠外铁剂。
研究设计与关键结果
- 3期双盲随机对照试验,中国29个中心,纳入154例未透析慢性肾病患者,按2:1随机接受罗沙司他或安慰剂每周三次口服8周。
- 主要终点第7–9周平均血红蛋白较基线变化:罗沙司他组升高1.9±1.2 g/dl vs 安慰剂组降低0.4±0.8 g/dl(P<0.001)。
- 铁调素较基线降低:罗沙司他组56.14±63.40 ng/ml vs 安慰剂组15.10±48.06 ng/ml。
- 总胆固醇较基线降低:罗沙司他组40.6 mg/dl vs 安慰剂组7.7 mg/dl。
- 不良事件:高钾血症和代谢性酸中毒在罗沙司他组比安慰剂组更常见。
- 18周开放标签期罗沙司他对血红蛋白的纠正和维持疗效持续。
证据类型、等级与局限
- 证据类型:3期随机双盲安慰剂对照试验。
- 资助方:FibroGen及FibroGen(中国)医疗科技发展;临床试验注册号NCT02652819。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者结论认为,在中国未透析慢性肾病患者中,罗沙司他组8周后平均血红蛋白水平高于安慰剂组,18周开放标签期疗效持续。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with chronic kidney disease, roxadustat increased levels of endogenous erythropoietin to within or near the physiologic range, along with increasing hemoglobin levels and improving iron homeostasis. Additional data are needed regarding the efficacy and safety of roxadustat for the treatment of anemia in patients with chronic kidney disease who are not undergoing dialysis.
METHODS: In this phase 3 trial conducted at 29 sites in China, we randomly assigned 154 patients with chronic kidney disease in a 2:1 ratio to receive roxadustat or placebo three times a week for 8 weeks in a double-blind manner. All the patients had a hemoglobin level of 7.0 to 10.0 g per deciliter at baseline. The randomized phase of the trial was followed by an 18-week open-label period in which all the patients received roxadustat; parenteral iron was withheld. The primary end point was the mean change from baseline in the hemoglobin level, averaged over weeks 7 through 9.
RESULTS: During the primary-analysis period, the mean (±SD) change from baseline in the hemoglobin level was an increase of 1.9±1.2 g per deciliter in the roxadustat group and a decrease of 0.4±0.8 g per deciliter in the placebo group (P<0.001). The mean reduction from baseline in the hepcidin level (associated with greater iron availability) was 56.14±63.40 ng per milliliter in the roxadustat group and 15.10±48.06 ng per milliliter in the placebo group. The reduction from baseline in the total cholesterol level was 40.6 mg per deciliter in the roxadustat group and 7.7 mg per deciliter in the placebo group. Hyperkalemia and metabolic acidosis occurred more frequently in the roxadustat group than in the placebo group. The efficacy of roxadustat in hemoglobin correction and maintenance was maintained during the 18-week open-label period.
CONCLUSIONS: In Chinese patients with chronic kidney disease who were not undergoing dialysis, those in the roxadustat group had a higher mean hemoglobin level than those in the placebo group after 8 weeks. During the 18-week open-label phase of the trial, roxadustat was associated with continued efficacy. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652819.).
参考来源
- Chen N, Hao C, Peng X, et al. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. N Engl J Med. 2019. PMID: 31340089. doi:10.1056/NEJMoa1813599
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。